This analysis reveals a value proposition in drug development through innovative trial design and optimization efforts.
Value can be introduced into the clinical drug development process by increasing the probability of success, and through product differentiation. Quality-by-design tools, expected in formulation optimization, are not common in trial design and program optimization. In this paper, I spotlight recent efforts to incorporate these methods and make suggestions for value-driven clinical development. Value-driven product development is introduced by noting the earlier history outside the pharmaceutical sector. A description of innovations in trial design and program structure highlights the recent focus on inserting value into the drug development process. Shrewdly designed trials can provide higher-quality data with fewer subjects and resources, a timelier basis, and more value for companies. There is a value in planning: plan for value.
No takes yet. Share an insight, caveat, or question.
Christopher D. Breder (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: